Lokken Investment Group LLC Acquires Shares of 14,299 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Lokken Investment Group LLC purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 14,299 shares of the biopharmaceutical company's stock, valued at approximately $347,000.

A number of other hedge funds have also recently bought and sold shares of CPRX. Steward Partners Investment Advisory LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $27,000. Park Square Financial Group LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $29,000. Farther Finance Advisors LLC lifted its holdings in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 1,495 shares during the last quarter. Sound Income Strategies LLC acquired a new stake in Catalyst Pharmaceuticals during the 1st quarter worth approximately $64,000. Finally, GAMMA Investing LLC lifted its holdings in Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 579 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Six analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $32.83.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Preethi Sundaram sold 2,324 shares of the business's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $26.41, for a total value of $61,376.84. Following the transaction, the insider directly owned 42,681 shares of the company's stock, valued at $1,127,205.21. The trade was a 5.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Gary Ingenito sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the transaction, the insider directly owned 68,873 shares in the company, valued at $1,630,912.64. This represents a 74.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 247,924 shares of company stock worth $5,879,369. Corporate insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Trading Down 2.6%

NASDAQ CPRX traded down $0.57 during midday trading on Tuesday, hitting $21.05. The company had a trading volume of 298,716 shares, compared to its average volume of 1,131,882. The company has a market capitalization of $2.57 billion, a PE ratio of 13.41, a P/E/G ratio of 0.89 and a beta of 0.66. The firm has a 50-day moving average price of $23.45 and a 200-day moving average price of $22.90. Catalyst Pharmaceuticals, Inc. has a twelve month low of $15.34 and a twelve month high of $26.58.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.